Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study.
Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study.
复制标题
左旋咪唑与重组白介素 2 (IL-2) 联合治疗晚期肾细胞癌：一项 II 期研究。
DOI：
10.1097/00000421-199804000-00008
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Tschetter,LK
中科院分区：
文献类型：
--
作者：
Creagan,ET;Hestorff,RD;Suman,VJ;Mailliard,JA;Nair,S;Krook,JE;Kugler,JW;MarschkeJr,RF;Michalak,JC;Tschetter,LK
采用白细胞介素2(IL-2)和淋巴因子激活的杀伤细胞(LAK)的过继免疫治疗(AI)是一种将免疫激活的细胞注射给癌症宿主以试图介导肿瘤消退的抗肿瘤方法。左旋咪唑(Lev)是一种免疫兴奋剂，已被认为对多种癌症具有治疗效果。在重组IL-2加LEV的I期试验后，该组合的II期试验在晚期肾癌患者中进行。治疗方案为IL-2 3×106U/m2，每日×5次，LEV 50 mg/m2，口服，每日3次×5次，22例患者中仅1例复发。这是一个部分回归，持续85天。治疗失败(拒绝、进展或因毒性而停止研究)的中位时间为36天。唯一报道的4级毒性是昏昏欲睡。该方案不推荐用于晚期肾癌患者的进一步测试。
Adoptive immunotherapy (AI) with interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells is an antineoplastic modality in which immune-activated cells are administered to a host having cancer in an attempt to mediate tumor regression. Levamisole (LEV), an immune stimulant, has been suggested as having therapeutic effectiveness in a variety of cancers. After a phase I trial of recombinant IL-2 plus LEV, a phase II trial of this combination was conducted in patients who had advanced renal cell carcinoma. The regimen was IL-2 at 3× 10 6 U/m 2 daily× 5 plus LEV at 50 mg/m 2 perorally three times a day× 5. Only one of the 22 eligible patients had a regression. It was a partial regression, 85 days in duration. The median time to treatment failure (refusal, progression, or off study because of toxicity) was 36 days. The only grade 4 toxicity reported was lethargy. This regimen is not recommended for further testing in patients who have advanced renal cell carcinoma.